Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1149-1156

  Subbarayan, Pochi R ^a   Sarkar, Malancha ^b   Nelson, Grodonoff ^b   Benitez, Edilberto ^b   Singhal, Shebani ^c   Ardalan, Bach ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Department of Biology   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Chemoresistance; HT29; mRNA quantification; Real time PCR; Translational regulation

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOROURIDINE; MESSENGER RNA; PROTEIN P53; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE; TRYPAN BLUE; URACIL DERIVATIVE;

ARTICLE; CANCER CELL; CELL LINE; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INDUCTION; ENZYME METABOLISM; ENZYME REPRESSION; GENE EXPRESSION; GENOME; HUMAN; HUMAN CELL; IC 50; IMMUNODETECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TERMINALLY ILL PATIENT; TREATMENT FAILURE;

COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; FLUOROURACIL; HT29 CELLS; HUMANS; PYRIMIDINES; RNA, MESSENGER; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953768628     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Roberti A, La Sala D and Cinti C: Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 207: 571-581, 2006.
2. Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A and Preusser P: New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 700: 1558-1577, 2004.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
4. Rustum YM: Thymidylate synthase: a critical target in cancer therapy? Front Biosci 9: 2467-2473, 2004.
5. Link KH, Kornmann M, Butzer U, Leder G, Sunelaitis E, Pillasch J, Salonga D, Danenberg KD, Danenberg PV and Beger HG: Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer 89: 288-296, 2000.
6. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine Phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
7. Leichman L, Lenz HJ, Leichman CG, Groshen S, Danenberg K, Baranda J, Spears CP, Boswell W, Silberman H and Ortega A: Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 31A: 1306-1310, 1995.
8. Tai N, Schmitz JC, Liu J, Lin X, Bailly M, Chen TM and Chu E: Translational autoregulation of thymidylate synthase and dihydrofolate reductase. Front Biosci 9: 2521-2526, 2004.
9. Liu J, Schmitz JC, Lin X, Tai N, Yan W, Farrell M, Bailly M, Chen T and Chu E: Thymidylate synthase as a translational regulator of cellular gene expression. Biochim Biophys Acta 1587: 174-182, 2002.
10. Fridman JS and Lowe SW: Control of apoptosis by p53. Oncogene 22: 9030-9040, 2003.
11. Muller PY, Janovjak H, Miserez AR and Dobbie Z: Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32: 1372-1379, 2002.
12. Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536, 2004.
13. Plasencia C, Rooney PH, Taron M, Martinez-Balibrea E, McLeod HL and Abad A: Chromosomal imbalance maps of human 5-FU-resistant colorectal cancer cell lines: implications in the analysis of 5-FU-acquired resistance mechanisms. Int J Oncol 22: 945-953, 2003.
14. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ and Zajac-Kaye M: Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351, 2004.
15. Banerjee D, Gorlick R, Liefshitz A, Danenberg K, Danenberg PC, Danenberg PV, Klimstra D, Jhanwar S, Cordon-Cardo C, Fong Y, Kemeny N and Bertino JR: Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res 60: 2365-2367, 2000. (Pubitemid 30262423)
16. Abal M, Bras-Goncalves R, Judde JG, Fsihi H, De Cremoux P, Louvard D, Magdelenat H, Robine S and Poupon MF: Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 23: 1737-1744, 2004.
17. Zacal N, Espiritu M, Singh G and Rainbow AJ: Increased BNip3 and decreased mutant p53 in cisplatin-sensitive PDT-resistant HT29 cells. Biochem Biophys Res Commun 331: 648-657, 2005.
18. Collot-Teixeira S, Bass J, Denis F and Ranger-Rogez S: Human tumor suppressor p53 and DNA viruses. Rev Med Virol 14: 301-319, 2004.
19. Benhattar J, Cerottini JP, Saraga E, Metthez G and Givel JC: p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69: 190-192, 1996.
20. Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV and Leichman LP: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4: 1227-1234, 1998. (Pubitemid 28213334)
21. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP and Leichman CG: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998.
22. Kikuchi-Yanoshita R, Konishi M, Ito S, Seki M, Tanaka K, Maeda Y, Iino H, Fukayama M, Koike M and Mori T: Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 52: 3965-3971, 1992.
23. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ and Pinedo HM: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587: 194-205, 2002.
24. Kim HK, Choi IJ, Kim HS, Kim JH, Kim E, Park IS, Chun JH, Kim IH, Kim IJ, Kang HC, Park JH, Bae JM, Lee JS and Park JG: DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys Res Commun 316: 781-789, 2004.
25. Berg RW, Ferguson PJ, DeMoor JM, Vincent MD and Koropatnick J: The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: Shoot the messenger. Current Drug Targets 3: 297-309, 2002.